NEW YORK (GenomeWeb) – Response Genetics today said it has executed a commercial agreement with the Knight Diagnostic Laboratories at Oregon Health & Science University to launch a next-generation sequencing-based lung cancer panel.

The Knight Diagnostic-developed panel provides "full gene sequencing of the actionable genes for lung cancer rather than detection only of so-called hot spots," Response Genetics said. It added that it expects to market the panel immediately.

Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.